still screen stretch
last night deliv result believ net posit
quarter said continu struggl balanc achiev long-term
target rel valuat versu peer posit beat
revenu forecast earli close euroimmun
better organ growth balanc favor fx organ
upsid came discoveri analyt solut da segment
encourag follow sever quarter under-perform vs life scienc tool
peer specif manag highlight stronger perform biopharma
expect consist commentari earn organ
top-lin beat growth broad-bas across region lsd revenu growth
america augment hsd asia low-teen europ compani
continu make headway new product
contribut modest
convers miss expect guidanc ebit million
surpris consid three factor drive better top-lin perform
flow bottom line manag attribut miss
higher variabl incent compens quarter believ
forecast guidanc deliv last quarter ep beat
driven lower expect tax rate vs model lower
forecast share count euroimmun compani project
signific ramp revenu drive revenu guidanc million
previou forecast major driver euroimmun ep accret
financ acquisit fund million
revolv ultim struggl model hsd long-term organ revenu growth
op margin context
view valuat expens rel life scienc tool peer reiter
underweight rate rais price target given better
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
last night deliv result believ net posit
quarter said continu struggl balanc achiev long-term target
rel valuat versu peer posit beat revenu
forecast earli close euroimmun better organ
growth balanc favor fx organ upsid came discoveri
 analyt solut da segment encourag follow sever quarter
stronger perform biopharma expect consist commentari
earn organ top line beat growth broad-bas across
region lsd revenu growth america augment hsd asia low-
teen europ compani continu make headway new product launch
although increment contribut modest
convers miss expect guidanc ebit million
surpris consid three factor drive better top-lin perform
flow bottom line manag attribut miss higher variabl
incent compens quarter believ forecast
guidanc deliv last quarter ep beat driven lower
expect tax rate vs model lower forecast share count
euroimmun compani project signific ramp revenu drive
revenu guidanc million previou forecast major driver
euroimmun ep accret financ acquisit
fund million revolv ultim struggl model hsd long-term
organ revenu growth op margin
context view valuat expens rel life scienc tool peer
reiter underweight rate
rais price target better visibl
manag guidanc price repres ebitda
million prior pt repres prior ebitda forecast million
initi guidanc assum organ growth full-year
revenu expect rang billion repres increas
y/i revenu guidanc assum million tailwind fx
million contribut euroimmun euroimmun acquisit expect
provid tailwind around guid organ growth
geograph compani expect msd organ growth america
europ along hsd growth asia includ guidanc adjust gross margin
expans along sg increas respect
result oper margin anticip improv addit
assum tax rate dilut share count million
compani anticip tax rate would repres increas y/i
result modest headwind tax reform combin unfavor earn
distribut euroimmun
guid ep includ accret
euroimmun compani expect revenu million
repres msd organ growth ep expect rang
call newborn screen growth driver within diagnost
franchis although compani comment specif perform
 remind busi declin due modest birth
rate approxim global market share newborn screen first
trimest prenat risk assess strong brand broad global channel
compani expect high single-digit growth newborn screen driven
three factor birth rate penetr screen number test
perform per babi market outsid us western europ repres
signific opportun recent strength busi driven menu
expans china enabl new mass spectrometri technolog
allow test per sampl overal screen penetr roughli china
averag util test per newborn util ms techniqu lower
roughli compani also see immens opportun india
babi screen shown chart approxim million
birth year global perkinelm estim new babi screen
market test perform per child
guidanc guidanc y/i ebit barclay inc
leader newborn screen particularli sensit chang
global birth rate follow broad decreas birth appear trend
revers cdc report increas addit
birth declin europ though increas china due end
one-child polici remind perkinelm earn call compani note
newborn screen busi slightli quarter
entir surpris given recent commentari slow birth rate still
compani state past quarter newborn screen busi
remain strong due menu expans penetr screen util
per babi remain low emerg market countri util per babi
roughli test compani note consid number
test screen notabl effect birth rate would repres risk
compani
y/i growth birth rate region
proxi birth rate note deliveri weak declin
similar result sinc stack growth mute
declin way track newborn screen trend
track hca quarterli commentari deliveri compar annual
birth rate report lag hca commentari give us
real-tim view market trend
millionsnorth americawestern europechinarest worldtotalnumb per stateseuropean union barclay inc
biopharma result improv manag attribut year-end
budget flush look forward continu favor exposur peer greater
biopharma product exposur biopharma busi
revenu grew organ said call compani cite low
double-digit growth pharma biotech includ hsd growth product
addit onesourc compani servic offer continu key growth
driver onesourc lab servic offer continu benefit outsourc
trend biopharma major area focu growth higher servic revenu
result impli biopharma product busi high-singl digit grower
quarter compani biopharma tool predominantli use discoveri
front end research activ biopharma sponsor unlik peer lack
major presenc liquid chromatographi led lower rel growth rate
within biopharma said given weaker margin profil faster growth
busi pressur margin da segment
biopharma mix compani
note alloc servic revenu research/product total
made two signific portfolio chang includ
acquisit euroimmun divestitur medic imag busi
decemb complet major acquisit euroimmun
euroimmun global manufactur diagnost workflow focu
autoimmun test grow presenc infecti diseas allergi test
euroimmun acquisit push mix faster grow market
addit top-lin growth one critiqu perkinelm
thesi compani structur lower growth profil peer
given lack biopharma product asset meaning industri presenc
take advantag recent improv end market euroimmun gener
around million revenu increas compound-annual-growth-rate past
year manag note expect growth low- mid-teen
compani doesnt want necessarili constrain
level growth
combin expand reach autoimmun allergi diagnost
market offer new infecti diseas capabl custom china
assum recent growth rate hold euroimmun could add pro-
forma top-lin growth
may complet divestitur medic imag
busi varex imag spin-off varian million agre
strateg rational exit busi face secular
declin better long-term growth return busi
abl re-deploy toward tuck-in share repurchas believ
biggest area pushback absorb near-term dilut although
impact modest medic imag busi gener million revenu
oper margin corpor averag ebitda
assum ebitda margin impli purchas price ebitda
compani believ good valu busi view non-cor
compani futur believ transact better streamlin
perkinelm oper although dilut weigh near-term ep growth
recent reorgan busi two new segment
diagnost discoveri analyt solut da help highlight
compani faster dx growth diagnost compani aggreg
clinic busi subject regulatori review includ screen test
reproduct health includ newborn screen infecti diseas test well
blood screen addit creat appli genom sub-seg
focu genom broadli compani remain optimist
around growth opportun within reproduct health emerg market infecti
diseas divest medic imag busi previous part segment
da segment hous product application-focus custom specif
area biopharma food safeti environment research industri perkinelm
view biopharma food safeti primari driver growth within end market
believ rational new oper structur make sens help
compani better align oper need custom
revenu mix sub-seg
revenu improv y/i million emb underli
organ growth roughli tailwind tulip euroimmun
acquisit tailwind fx revenu came ahead expect
guidanc due better organ growth favor fx contribut
euroimmun quarter solid top-lin result result strong perform
segment compani post diagnost da
compani post organ growth end market geographi
except academ end market declin low single-digit difficult
comp remain optimist around cadenc new product launch cite
new product contribut million revenu
revenu organ growth
revenu growth solid compani busi segment import
note due compani sale medic imag busi remov
compani diagnost segment
diagnost segment revenu revenu grew organ
fourth quarter growth driven genom solut along strong result
reproduct health compani note tulip result strong quarter
grow doubl digit addit euroimmun acquisit ad million
revenu describ observ close acquisit
euroimmun decemb expand compani presenc autoimmun
allergi diagnost model organ growth diagnost
discoveri analyt solut revenu revenu grew
organ quarter embed growth rate quarter hsd growth
food lsd declin
academ hsd growth industri ldd growth
environment ldd growth biopharma compani believ
industri end market like continu rebound strength biopharma
continu benefit strong result compani onesourc busi
perform well quarter model organ growth da
non-gaap ep increas y/i estim ep
benefit lower expect tax rate better fx
euroimmun acquisit
non-gaap ep growth
end market commentari solid quarter except
academ end market end market geographi grew organ biopharma
grew high single-digit driven broad strength across compani
product servic onesourc busi diagnost end market show strong
result organ growth led newborn screen prenat food end
market continu strong compani grow high single-digit quarter
environment end market acceler low double-digit growth low single-digit
growth industri end market grew low single-digit y/i although
manag commentari around health end market optimist
attribut difficult comp academ govern end market declin
low single-digit
geograph compani report high single-digit organ growth asia low
single-digit growth america low-teen growth europ china continu
growth engin mid-teen organ growth quarter bric region
broadli post solid growth compani see recoveri brazil perkinelm
look continu expand reach india recent tulip diagnost
acquisit compani enthusiast leverag tulip platform introduc
legaci euroimmun product market
perkinelm geograph divers rev
perkinelm revenu breakdown end market
gross margin prior year period
expect gross margin improv despit solid
organ growth rate quarter margin declin due neg mix dynam
result strength compani servic da busi carri gross
margin dilut compani averag expect continu
benefit lean manufactur initi margin
perkinelm gross margin ebitda margin
sg ex-stock comp expens decreas y/i repres
revenu sg leverag partial off-set increment expens form
euroimmun acquisit expens total sale flat y/i despit
increas invest diagnost da compani expect level
increas euroimmun acquisit close compani also focus new
product initi expect gener addit million revenu
perkinelm adjust sg trend
report adjust ebit margin y/i
compani benefit effici quarter partial off-set
increas stock-comp expens due euroimmun acquisit adjust
impact margin would expand quarter margin improv
segment da y/i diagnost y/i compani continu
target oper margin compani expect margin
improv driven posit euroimmun mix posit product mix
perkinelm ebit margin annual growth
cffo oper million quarter capital-expenditure
million repres revenu million quarter million
expect compani repurchas share quarter
follow divestitur medic imag busi subsequ tulip
euroimmun acquisit cash balanc million
perkinelm use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net net researchprior yearprior quarter barclay inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
